Our proprietary PETization platform enables the rapid translation of therapeutic monoclonal antibodies (mAbs) between species.
Our mAbs are uniquely designed to be accepted by a patient's immune system as "native," a property we refer to as "100% species-specificity."
Our most advanced therapies in development are focused on treatments within two general areas: chronic pain in both dogs and cats, and inflammatory disease in dogs.
We believe biologic therapies offer significant advantages over current treatments in both these areas.
Our team of scientists and veterinarians are working to investigate further opportunities for new biologic therapies.
20-21 November 2014
London Vet Show, London, U.K.
17-21 January 2015
North American Veterinary Community Conference, FL, U.S.
15-19 February 2015
Western Veterinary Conference, Las Vegas, NV, U.S.
2-5 April 2015
British Small Animal Veterinary Association Conference, Birmingham, U.K.
3–6 June 2015
American College of Veterinary Internal Medicine Forum, IN, U.S.
National Institute for Bioprocessing Research and Training
Fosters Avenue, Mount Merrion
Blackrock, Co. Dublin
P: +353 (1) 215 8100
Level 8, 31 Queen Street
P: +61 (3) 9610 4100
100 Pine Street
San Francisco, CA